Susquehanna International Group’s Progenics Pharmaceuticals Inc PGNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-65,909
| Closed | -$250K | – | 11411 |
|
|
2020
Q1 | $250K | Buy |
65,909
+16,961
| +35% | +$73.1K | ﹤0.01% | 8314 |
|
|
2019
Q4 | $249K | Sell |
48,948
-45,646
| -48% | -$241K | ﹤0.01% | 8369 |
|
|
2019
Q3 | $478K | Sell |
94,594
-55,859
| -37% | -$279K | ﹤0.01% | 7403 |
|
|
2019
Q2 | $928K | Buy |
+150,453
| New | +$725K | ﹤0.01% | 5838 |
|
|
2019
Q1 | – | Sell |
-343,974
| Closed | -$1.56M | – | 10321 |
|
|
2018
Q4 | $1.45M | Buy |
343,974
+107,007
| +45% | +$545K | ﹤0.01% | 4039 |
|
|
2018
Q3 | $1.49M | Sell |
236,967
-10,024
| -4% | -$77K | ﹤0.01% | 4501 |
|
|
2018
Q2 | $1.99M | Sell |
246,991
-140,593
| -36% | -$1.07M | ﹤0.01% | 4037 |
|
|
2018
Q1 | $2.89M | Buy |
387,584
+162,883
| +72% | +$1.08M | ﹤0.01% | 3314 |
|
|
2017
Q4 | $1.34M | Buy |
224,701
+102,322
| +84% | +$622K | ﹤0.01% | 4665 |
|
|
2017
Q3 | $901K | Buy |
+122,379
| New | +$777K | ﹤0.01% | 5459 |
|
|
2017
Q2 | – | Sell |
-137,223
| Closed | -$1.01M | – | 10137 |
|
|
2017
Q1 | $1.29M | Sell |
137,223
-60,393
| -31% | -$603K | ﹤0.01% | 4589 |
|
|
2016
Q4 | $1.71M | Buy |
197,616
+183,938
| +1,345% | +$1.36M | ﹤0.01% | 4410 |
|
|
2016
Q3 | $87K | Buy |
+13,678
| New | +$82.7K | ﹤0.01% | 7996 |
|
|
2016
Q2 | – | Sell |
-57,326
| Closed | -$277K | – | 9658 |
|
|
2016
Q1 | $250K | Buy |
57,326
+23,590
| +70% | +$105K | ﹤0.01% | 7568 |
|
|
2015
Q4 | $207K | Sell |
33,736
-84,606
| -71% | -$555K | ﹤0.01% | 8369 |
|
|
2015
Q3 | $677K | Sell |
118,342
-119,434
| -50% | -$916K | ﹤0.01% | 6536 |
|
|
2015
Q2 | $1.77M | Buy |
237,776
+69,895
| +42% | +$423K | ﹤0.01% | 4976 |
|
|
2015
Q1 | $1M | Sell |
167,881
-87,107
| -34% | -$548K | ﹤0.01% | 5760 |
|
|
2014
Q4 | $1.93M | Buy |
254,988
+201,652
| +378% | +$1.21M | ﹤0.01% | 4527 |
|
|
2014
Q3 | $277K | Sell |
53,336
-52,776
| -50% | -$263K | ﹤0.01% | 8150 |
|
|
2014
Q2 | $457K | Sell |
106,112
-12,829
| -11% | -$49K | ﹤0.01% | 7650 |
|
|
2014
Q1 | $486K | Sell |
118,941
-52,999
| -31% | -$271K | ﹤0.01% | 6781 |
|
|
2013
Q4 | $916K | Buy |
171,940
+123,983
| +259% | +$545K | ﹤0.01% | 5666 |
|
|
2013
Q3 | $241K | Buy |
+47,957
| New | +$260K | ﹤0.01% | 7520 |
|
Other funds holding PGNX
Susquehanna International Group's PGNX Position: Q2 2020 in Review
Susquehanna International Group sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 65,909 shares — an estimated $250K sold.
Susquehanna International Group first reported a position in PGNX in Q3 2013 and held it in 24 quarters. The position peaked at $2.89M in Q1 2018. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.
- Susquehanna International Group reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
- Susquehanna International Group sold 65,909 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $250K.
- Susquehanna International Group first reported a position in Progenics Pharmaceuticals Inc in Q3 2013 and held it in 24 quarters.
- Susquehanna International Group's Progenics Pharmaceuticals Inc position peaked at $2.89M in Q1 2018.
- 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.
Based on Susquehanna International Group's 13F filing for Q2 2020, filed 14 Aug 2020.